148 related articles for article (PubMed ID: 19772921)
21. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation.
Heinemann FM; Rebmann V; Witzke O; Philipp T; Broelsch CE; Grosse-Wilde H
Transplantation; 2007 Mar; 83(6):706-11. PubMed ID: 17414702
[TBL] [Abstract][Full Text] [Related]
22. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30.
Dong W; Shunliang Y; Weizhen W; Qinghua W; Zhangxin Z; Jianming T; He W
Transpl Immunol; 2006 Jun; 16(1):41-5. PubMed ID: 16701175
[TBL] [Abstract][Full Text] [Related]
23. High serum soluble CD30 does not predict acute rejection in liver transplant patients.
Matinlauri I; Höckerstedt K; Isoniemi H
Transplant Proc; 2006 Dec; 38(10):3601-4. PubMed ID: 17175343
[TBL] [Abstract][Full Text] [Related]
24. High pretransplantation soluble CD30 levels: impact in renal transplantation.
Giannoli C; Bonnet MC; Perrat G; Houillon A; Reydet S; Pouteil-Noble C; Villar E; Lefrançois N; Morelon E; Dubois V
Transplant Proc; 2007 Oct; 39(8):2574-5. PubMed ID: 17954178
[TBL] [Abstract][Full Text] [Related]
25. Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft.
Pavlova Y; Viklicky O; Slatinska J; Bürgelova M; Süsal C; Skibova J; Honsová E; Striz I; Kolesar L; Slavcev A
Transpl Immunol; 2011 Jul; 25(1):72-6. PubMed ID: 21376809
[TBL] [Abstract][Full Text] [Related]
26. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation.
Sengul S; Keven K; Gormez U; Kutlay S; Erturk S; Erbay B
Transplantation; 2006 Apr; 81(8):1216-9. PubMed ID: 16641611
[TBL] [Abstract][Full Text] [Related]
27. sCD30, interleukin-1beta-converting enzyme and anti-Annexin V autoantibodies concentrations in heart transplant recipients.
Zeglen S; Zakliczyński M; Nozyński J; Rogala B; Zembala M
Transpl Immunol; 2006 Nov; 16(3-4):227-31. PubMed ID: 17138058
[TBL] [Abstract][Full Text] [Related]
28. Early post-transplant immune monitoring can predict long-term kidney graft survival: soluble CD30 levels, anti-HLA antibodies and IgA-anti-Fab autoantibodies.
Amirzargar MA; Amirzargar A; Basiri A; Hajilooi M; Roshanaei G; Rajabi G; Mohammadiazar S; Solgi G
Hum Immunol; 2014 Jan; 75(1):47-58. PubMed ID: 24055694
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
Cinti P; Pretagostini R; Arpino A; Tamburro ML; Mengasini S; Lattanzi R; De Simone P; Berloco P; Molajoni ER
Transplantation; 2005 May; 79(9):1154-6. PubMed ID: 15880060
[TBL] [Abstract][Full Text] [Related]
30. Predicting renal graft failure by sCD30 levels and de novo HLA antibodies at 1year post-transplantation.
Wang D; Wu G; Chen J; Yu Z; Wu W; Yang S; Tan J
Transpl Immunol; 2012 Jun; 26(4):235-9. PubMed ID: 22446727
[TBL] [Abstract][Full Text] [Related]
31. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
Shooshtarizadeh T; Mohammadali A; Ossareh S; Ataipour Y
Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
[TBL] [Abstract][Full Text] [Related]
32. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
Solgi G; Amirzagar AA; Pourmand G; Mehrsai AR; Taherimahmoudi M; Baradaran N; Nicknam MH; Ebrahimi Rad MR; Saraji A; Asadpoor AA; Moheiydin M; Nikbin B
Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of pre- and posttransplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection.
Kim KH; Oh EJ; Jung ES; Park YJ; Choi JY; Kim DG; Lee KY; Kang CS
Transplant Proc; 2006 Jun; 38(5):1429-31. PubMed ID: 16797323
[TBL] [Abstract][Full Text] [Related]
34. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
Vaidya S; Partlow D; Barnes T; Thomas P; Gugliuzza K
Clin Transplant; 2006; 20(4):461-4. PubMed ID: 16842522
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection.
Pelzl S; Opelz G; Daniel V; Wiesel M; Süsal C
Transplantation; 2003 Feb; 75(3):421-3. PubMed ID: 12589170
[TBL] [Abstract][Full Text] [Related]
36. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis.
Chen Y; Tai Q; Hong S; Kong Y; Shang Y; Liang W; Guo Z; He X
Transplantation; 2012 Nov; 94(9):911-8. PubMed ID: 23052636
[TBL] [Abstract][Full Text] [Related]
37. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
Billing H; Sander A; Süsal C; Ovens J; Feneberg R; Höcker B; Vondrak K; Grenda R; Friman S; Milford DV; Lucan M; Opelz G; Tönshoff B
Transpl Int; 2013 Mar; 26(3):331-8. PubMed ID: 23279372
[TBL] [Abstract][Full Text] [Related]
38. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes.
Yang JL; Hao HJ; Zhang B; Liu YX; Chen S; Na YQ
Transplant Proc; 2008 Dec; 40(10):3381-3. PubMed ID: 19100394
[TBL] [Abstract][Full Text] [Related]
39. Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant?
Satoskar AA; Lehman AM; Nadasdy GM; Sedmak DD; Pesavento TE; Henry ML; Pelletier RP; Ferguson RM; Nadasdy T
Clin Transplant; 2008; 22(1):61-7. PubMed ID: 18217907
[TBL] [Abstract][Full Text] [Related]
40. Posttransplant sCD30 as a biomarker to predict kidney graft outcome.
Süsal C; Opelz G
Clin Chim Acta; 2012 Sep; 413(17-18):1350-3. PubMed ID: 22037199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
